Kohde Pharma

Kohde Pharma is a Finnish biotechnology company dedicated to the discovery and development of novel precision oncology therapeutics. The company specializes in targeting RNA-binding proteins (RBPs), a critical but largely untapped class of proteins that regulate post-transcriptional gene expression and are frequently dysregulated in cancer. By leveraging its proprietary drug discovery platform, Kohde Pharma identifies small molecule inhibitors designed to disrupt oncogenic RBP-RNA interactions. The company's approach aims to provide new treatment options for hard-to-treat malignancies that have become resistant to standard therapies. Currently in the pre-clinical stage, Kohde Pharma is advancing a pipeline of first-in-class candidates focused on high-value oncology targets.